Fawaz Charbel S, Martel Philippe, Leo Damiana, Trudeau Louis-Eric
Department of Pharmacology, Groupe de Recherche sur le Système Nerveux Central, Faculty of Medicine, Université de Montréal, Quebec, H3C 3J7, Canada.
BMC Neurosci. 2009 Aug 14;10:96. doi: 10.1186/1471-2202-10-96.
Neurotensin (NT) is known to act on dopamine (DA) neurons at the somatodendritic level to regulate cell firing and secondarily enhance DA release. In addition, anatomical and indirect physiological data suggest the presence of NT receptors at the terminal level. However, a clear demonstration of the mechanism of action of NT on dopaminergic axon terminals is lacking. We hypothesize that NT acts to increase DA release by inhibiting the function of terminal D2 autoreceptors. To test this hypothesis, we used fast-scan cyclic voltammetry (FCV) to monitor in real time the axonal release of DA in the nucleus accumbens (NAcc).
DA release was evoked by single electrical pulses and pulse trains (10 Hz, 30 pulses). Under these two stimulation conditions, we evaluated the characteristics of DA D2 autoreceptors and the presynaptic action of NT in the NAcc shell and shell/core border region. The selective agonist of D2 autoreceptors, quinpirole (1 microM), inhibited DA overflow evoked by both single and train pulses. In sharp contrast, the selective D2 receptor antagonist, sulpiride (5 microM), strongly enhanced DA release triggered by pulse trains, without any effect on DA release elicited by single pulses, thus confirming previous observations. We then determined the effect of NT (8-13) (100 nM) and found that although it failed to increase DA release evoked by single pulses, it strongly enhanced DA release evoked by pulse trains that lead to prolonged DA release and engage D2 autoreceptors. In addition, initial blockade of D2 autoreceptors by sulpiride considerably inhibited further facilitation of DA release generated by NT (8-13).
Taken together, these data suggest that NT enhances DA release principally by inhibiting the function of terminal D2 autoreceptors and not by more direct mechanisms such as facilitation of terminal calcium influx.
已知神经降压素(NT)在树突体水平作用于多巴胺(DA)神经元,以调节细胞放电并继而增强DA释放。此外,解剖学和间接生理学数据表明在终末水平存在NT受体。然而,缺乏NT对多巴胺能轴突终末作用机制的明确证据。我们假设NT通过抑制终末D2自身受体的功能来增加DA释放。为了验证这一假设,我们使用快速扫描循环伏安法(FCV)实时监测伏隔核(NAcc)中DA的轴突释放。
单个电脉冲和脉冲串(10Hz,30个脉冲)可诱发DA释放。在这两种刺激条件下,我们评估了NAcc壳层和壳层/核心边界区域中DA D2自身受体的特征以及NT的突触前作用。D2自身受体的选择性激动剂喹吡罗(1μM)抑制了单个和脉冲串诱发的DA溢出。形成鲜明对比的是,选择性D2受体拮抗剂舒必利(5μM)强烈增强了脉冲串触发的DA释放,而对单个脉冲诱发的DA释放没有任何影响,从而证实了先前的观察结果。然后我们确定了NT(8 - 13)(100 nM)的作用,发现尽管它未能增加单个脉冲诱发的DA释放,但它强烈增强了由脉冲串诱发的DA释放,这些脉冲串导致DA释放延长并激活D2自身受体。此外,舒必利对D2自身受体的初始阻断显著抑制了NT(8 - 13)对DA释放的进一步促进作用。
综上所述,这些数据表明NT主要通过抑制终末D2自身受体的功能来增强DA释放,而不是通过更直接的机制,如促进终末钙内流。